Ovid Therapeutics (OVID) Appoints Kevin Norrett as Chief Business Officer
Ovid Therapeutics (OVID) Appoints Kevin Norrett as Chief Business Officer.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Ovid Therapeutics Inc. (NASDAQ:OVID) is one of the 10 Fastest Growing Tech Penny Stocks to Buy .
On July 8, 2026, Ovid Therapeutics Inc. (NASDAQ:OVID) announced several strategic appointments. Kevin Norrett will join Ovid as chief business officer to lead business and corporate development functions, as well as strategic partnerships. Most recently, Norrett served as chief business officer at Soleno Therapeutics.
Ovid also promoted Charles Carter to CFO, where Carter will lead business and financial operations. Carter succeeds Jeffrey Rona, who will remain a long-term advisor to the company through 2027. Victoria Fort was promoted to chief strategy officer, leading enterprise strategy, investor relations, and operational growth initiatives.
In May, Ovid Therapeutics reported Q1 EPS of (12c), compared with the consensus of (11c). CEO Meg Alexander said the first quarter reflected "focused execution" and continued progress across the company's pipeline of small molecule medicines for intractable brain conditions. Alexander said development programs remain on track, the clinical organization has expanded, and the company expects to be well capitalized into 2029.
Ovid Therapeutics Inc. (NASDAQ:OVID) develops small-molecule medicines for brain disorders, including epilepsies and seizure-related neurological disorders in the United States.
While we acknowledge the potential of OVID as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock .
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy .
Sinergia Empresarial continuará el seguimiento de esta información sobre ovid Therapeutics (OVID) Appoints Kevin Norrett as Chief Business Officer y ampliará la cobertura conforme se confirmen nuevos elementos relevantes para el ecosistema empresarial.
